Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.

Ikeda T, Fukuda M, Nakamura Y, Kinoshita A, Senju H, Nakano H, Kitazaki T, Ogawara D, Taniguchi H, Motoshima K, Yamaguchi H, Nakatomi K, Shimada M, Nagashima S, Tsukamoto K, Kohno S; Nagasaki Thoracic Oncology Group.

Cancer Chemother Pharmacol. 2014 Sep;74(3):497-502. doi: 10.1007/s00280-014-2527-4. Epub 2014 Jul 18.

PMID:
25034978
2.

A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.

Fukuda M, Nakamura Y, Kasai T, Nagashima S, Nakatomi K, Doi S, Nakano H, Takatani H, Fukuda M, Kinoshita A, Soda H, Tsukamoto K, Oka M, Kohno S; Nagasaki Thoracic Oncology Group.

J Thorac Oncol. 2009 Jun;4(6):741-5. doi: 10.1097/JTO.0b013e3181a52946.

3.

Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.

Hirose T, Nakashima M, Shirai T, Kusumoto S, Sugiyama T, Yamaoka T, Okuda K, Ohnishi T, Ohmori T, Adachi M.

Lung Cancer. 2011 Sep;73(3):345-50. doi: 10.1016/j.lungcan.2010.12.015. Epub 2011 Jan 31.

PMID:
21277039
4.

A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.

Inoue A, Ishimoto O, Fukumoto S, Usui K, Suzuki T, Yokouchi H, Maemondo M, Kanbe M, Ogura S, Harada T, Oizumi S, Harada M, Sugawara S, Fukuhara T, Nukiwa T.

Ann Oncol. 2010 Apr;21(4):800-3. doi: 10.1093/annonc/mdp384. Epub 2009 Oct 13.

PMID:
19825887
5.

A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.

Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, Katakami N, Shibuya M, Saijo N, Fukuoka M.

Clin Lung Cancer. 2014 Mar;15(2):96-102. doi: 10.1016/j.cllc.2013.11.006. Epub 2013 Nov 14.

PMID:
24361248
6.

A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.

Inoue A, Yamazaki K, Maemondo M, Suzuki T, Kimura Y, Kanbe M, Isobe H, Nishimura M, Saijo Y, Nukiwa T.

J Thorac Oncol. 2006 Jul;1(6):551-5.

7.

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P.

Eur J Cancer. 2011 Oct;47(15):2322-30. doi: 10.1016/j.ejca.2011.05.020. Epub 2011 Jun 16.

PMID:
21684151
8.

Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study.

Yana T, Negoro S, Takada M, Yokota S, Takada Y, Sugiura T, Yamamoto H, Sawa T, Kawahara M, Katakami N, Ariyoshi Y, Fukuoka M; West Japan Thoracic Oncology Group.

Invest New Drugs. 2007 Jun;25(3):253-8. Epub 2006 Oct 13.

PMID:
17039404
9.

A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.

Nogami N, Hotta K, Kuyama S, Kiura K, Takigawa N, Chikamori K, Shibayama T, Kishino D, Hosokawa S, Tamaoki A, Harita S, Tabata M, Ueoka H, Shinkai T, Tanimoto M.

Lung Cancer. 2011 Oct;74(1):80-4. doi: 10.1016/j.lungcan.2011.01.018. Epub 2011 Feb 18.

10.

Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer.

Igawa S, Ryuge S, Fukui T, Otani S, Kimura Y, Katono K, Takakura A, Kubota M, Mitsufuji H, Katagiri M, Yanase N, Masuda N.

Int J Clin Oncol. 2010 Oct;15(5):447-52. doi: 10.1007/s10147-010-0085-2. Epub 2010 May 13.

PMID:
20464623
11.

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.

J Clin Oncol. 2009 Oct 1;27(28):4787-92. doi: 10.1200/JCO.2009.23.1548. Epub 2009 Aug 31.

PMID:
19720897
12.

Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.

Kobayashi M, Matsui K, Iwamoto Y, Ebi N, Oizumi S, Takeda K, Sawa T, Shibata K, Saka H, Imamura F, Seki N, Saito H, Goto I, Nakagawa K; West Japan Oncology Group.

J Thorac Oncol. 2010 Jul;5(7):1075-80. doi: 10.1097/JTO.0b013e3181dd1591.

13.

Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.

Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T.

Respir Investig. 2014 May;52(3):190-4. doi: 10.1016/j.resinv.2013.12.005. Epub 2014 Jan 28.

PMID:
24853020
14.

A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.

Fukuda M, Soda H, Soejima Y, Fukuda M, Kinoshita A, Takatani H, Kasai T, Nagashima S, Kawabata S, Doi S, Kohno S, Oka M.

Cancer Chemother Pharmacol. 2006 Nov;58(5):601-6. Epub 2006 Feb 4.

PMID:
16463061
15.

Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423.

Chee CE, Jett JR, Bernath AM Jr, Foster NR, Nelson GD, Molina J, Nikcevich DA, Steen PD, Flynn PJ, Rowland KM Jr.

Cancer. 2010 May 15;116(10):2382-9. doi: 10.1002/cncr.24967.

16.

Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer.

Shimokawa T, Shibuya M, Kitamura K, Hosomi Y, Hibino S, Ota T, Iguchi M, Okamura T, Gemma A.

Int J Clin Oncol. 2009 Feb;14(1):63-9. doi: 10.1007/s10147-008-0802-2. Epub 2009 Feb 20.

PMID:
19225927
17.

Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.

Gajra A, Mehdi SA, Kirshner J, Newman N, Graziano SL.

Lung Cancer. 2001 May;32(2):189-96.

PMID:
11325490
18.

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.

Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Shimizu K, Imai H, Utsugi M, Iwasaki Y, Iijima H, Tsurumaki H, Yoshii A, Fueki N, Hisada T, Ishizuka T, Saito R, Mori M.

Lung Cancer. 2010 Jul;69(1):99-104. doi: 10.1016/j.lungcan.2009.09.012. Epub 2009 Oct 23.

PMID:
19853960
19.

A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Garst J, Herndon JE 2nd, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Maravich-May D, Anderson E, Crawford J.

Clin Drug Investig. 2006;26(5):257-66.

PMID:
17163259
20.

Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer.

Horvath L, Boyer M, Clarke S, Beale P, Beith J, Underhill C, Stockler M, Bishop J.

Lung Cancer. 2001 May;32(2):173-8. Review.

PMID:
11325488

Supplemental Content

Support Center